v3.26.1
Note 15 - Segments
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segments

NOTE 15 SEGMENTS

We manage our operations in two reportable segments - pharmaceutical and diagnostics. The following is a brief description of our reportable segments and a description of business activities conducted by our corporate operations.

Pharmaceutical — this segment consists of our operations in Chile, Mexico, Ireland, Israel, Spain, Brazil, and Uruguay, Rayaldee product sales, NGENLA® royalty and profit-sharing sales, and our pharmaceutical research and development.

Diagnostics — this segment primarily consists of clinical laboratory operations through BioReference and our point-of-care operations.

To provide greater transparency into the factors affecting segment profitability, the Company discloses significant expense categories for each reportable segment in the tables below. Our CODM is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Dr. Frost reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. Our CODM may discuss and review financial information at the Pharmaceutical and Diagnostic operating segment level. The CODM uses segment information to evaluate segment profitability, monitor trends, identify risks and opportunities, allocate resources (such as capital expenditures and R&D funding), and set strategic priorities (including new product development and market expansion). These expenses, along with segment revenue, are used to calculate gross margin, a key profitability metric that the CODM uses to assess segment performance. In computing operating income, none of the following items have been included: interest expense, other non-operating income and expenses, and income taxes. Segment operating income (expense) is total revenue, less cost of revenue and operating expenses relative to each segment. There are no significant inter-segment sales, nor is there any inter-segment allocation of interest expense or income taxes.

The following are descriptions of the significant expense categories included in the segment reporting tables below:

For the pharmaceutical segment:

•
Cost of product revenue: Represents the direct costs of manufacturing and distributing pharmaceutical products, including raw materials, manufacturing overhead, and distribution costs.
•
Selling, general and administrative (SG&A) expenses: Encompasses operating expenses such as salaries, marketing and advertising costs, and administrative overhead.
•
Research and development (R&D) expenses: Incurred in developing new pharmaceutical products, including costs related to research, clinical trials, and regulatory approvals.
•
Intangible asset amortization: Represents the periodic expensing of acquired intangible assets, such as patents and licenses.
•
Depreciation: Relates to the depreciation of property, plant, and equipment used in the segment's operations.

For the diagnostics segment:

•
Cost of service revenue: Includes the direct costs of providing diagnostic testing services, such as laboratory supplies, equipment costs, and labor costs.
•
Selling, general and administrative (SG&A) expenses: Similar to the Pharmaceuticals segment, includes salaries, marketing expenses, and administrative overhead.
•
Research and development (R&D) expenses: Incurred in developing new diagnostic products and services, including costs related to research, clinical studies, regulatory submissions, and new technology development.
•
Intangible asset amortization: Represents the periodic expensing of acquired intangible assets, such as intellectual property and customer relationships.
•
Other segment items: Primarily consists of gains and losses recognized on the sale of businesses or assets.
•
Depreciation: Relates to the depreciation of property, plant, and equipment used in the segment's operations.

The tables below present information about reported segments, unallocated corporate operations as well as geographic information for the six months ended June 30, 2026 and 2025:

 

 

 

For the three months ended June 30,

 

 

For the six months ended June 30,

 

(In thousands)

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Revenue from services:

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Diagnostics

 

 

74,549

 

 

 

101,101

 

 

 

146,735

 

 

 

203,945

 

Corporate

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

$

74,549

 

 

$

101,101

 

 

$

146,735

 

 

$

203,945

 

Revenue from products:

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical

 

$

42,941

 

 

$

40,743

 

 

$

80,984

 

 

$

75,585

 

Diagnostics

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Corporate

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

$

42,941

 

 

$

40,743

 

 

$

80,984

 

 

$

75,585

 

Revenue from transfer of intellectual property and other:

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical

 

$

46,090

 

 

$

14,963

 

 

$

60,058

 

 

$

27,229

 

Diagnostics

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Corporate

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

$

46,090

 

 

$

14,963

 

 

$

60,058

 

 

$

27,229

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical

 

$

25,101

 

 

$

25,022

 

 

$

47,399

 

 

$

47,836

 

Diagnostics

 

 

58,462

 

 

 

82,383

 

 

 

114,604

 

 

 

166,901

 

Corporate

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

$

83,563

 

 

$

107,405

 

 

$

162,003

 

 

$

214,737

 

Gross margin:

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical

 

$

63,930

 

 

$

30,684

 

 

$

93,643

 

 

$

54,978

 

Diagnostics

 

 

16,087

 

 

 

18,718

 

 

 

32,131

 

 

 

37,044

 

Corporate

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

$

80,017

 

 

$

49,402

 

 

$

125,774

 

 

$

92,022

 

Selling, general and administrative:

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical

 

$

13,916

 

 

$

13,197

 

 

$

28,121

 

 

$

25,907

 

Diagnostics

 

 

26,574

 

 

 

33,369

 

 

 

52,725

 

 

 

71,325

 

Corporate

 

 

12,434

 

 

 

13,031

 

 

 

20,685

 

 

 

21,451

 

 

$

52,924

 

 

$

59,597

 

 

$

101,531

 

 

$

118,683

 

Research and development:

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical

 

$

32,739

 

 

$

29,778

 

 

$

61,492

 

 

$

60,016

 

Diagnostics

 

 

294

 

 

 

484

 

 

 

606

 

 

 

1,022

 

Corporate

 

 

133

 

 

 

80

 

 

 

267

 

 

 

145

 

 

$

33,166

 

 

$

30,342

 

 

$

62,365

 

 

$

61,183

 

Amortization of intangible assets:

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical

 

$

16,436

 

 

$

16,415

 

 

$

32,869

 

 

$

32,525

 

Diagnostics

 

 

2,533

 

 

 

3,029

 

 

 

5,066

 

 

 

6,779

 

Corporate

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

$

18,969

 

 

$

19,444

 

 

$

37,935

 

 

$

39,304

 

Other segment items:

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Diagnostics

 

 

(18,070

)

 

 

—

 

 

 

(18,070

)

 

 

—

 

Corporate

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

$

(18,070

)

 

$

—

 

 

$

(18,070

)

 

$

—

 

Segment operating loss:

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical

 

$

839

 

 

$

(28,706

)

 

$

(28,839

)

 

$

(63,470

)

Diagnostics

 

 

4,756

 

 

 

(18,164

)

 

 

(8,196

)

 

 

(42,082

)

Corporate

 

 

(12,567

)

 

 

(13,111

)

 

 

(20,952

)

 

 

(21,596

)

 

$

(6,972

)

 

$

(59,981

)

 

$

(57,987

)

 

$

(127,148

)

 

 

 

For the three months ended June 30,

 

 

For the six months ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Depreciation and amortization:

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceutical

 

$

18,511

 

 

$

18,142

 

 

$

36,770

 

 

$

35,930

 

Diagnostics

 

 

3,883

 

 

 

4,885

 

 

 

7,810

 

 

 

10,584

 

Corporate

 

 

15

 

 

 

—

 

 

 

29

 

 

 

—

 

 

$

22,409

 

 

$

23,027

 

 

$

44,609

 

 

$

46,514

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

$

88,809

 

 

$

114,884

 

 

$

172,313

 

 

$

231,091

 

Ireland

 

 

41,663

 

 

 

11,742

 

 

 

51,343

 

 

 

17,221

 

Chile

 

 

16,429

 

 

 

16,003

 

 

 

31,299

 

 

 

30,535

 

Spain

 

 

8,451

 

 

 

6,724

 

 

 

16,501

 

 

 

13,164

 

Israel

 

 

—

 

 

 

139

 

 

 

(0

)

 

 

212

 

Mexico

 

 

7,042

 

 

 

6,297

 

 

 

13,982

 

 

 

12,526

 

Other

 

 

1,186

 

 

 

1,018

 

 

 

2,339

 

 

 

2,010

 

 

$

163,580

 

 

$

156,807

 

 

$

287,777

 

 

$

306,759

 

 

Segment assets for the two reportable segments in which we operate are shown in the following tables. Corporate assets are principally cash and are not allocated to an operating segment. Identifiable assets by segment are those assets that are used in our operations in each segment. The accounting policies of the segments are the same as those described in Note 3 summary of significant accounting policies.

 

 

 

June 30,

 

 

December 31,

 

(In thousands)

 

2026

 

 

2025

 

Assets:

 

 

 

 

 

 

Pharmaceutical

 

$

1,276,391

 

 

$

1,326,400

 

Diagnostics

 

 

347,510

 

 

 

349,095

 

Corporate

 

 

205,552

 

 

 

256,449

 

 

$

1,829,453

 

 

$

1,931,944

 

Goodwill:

 

 

 

 

 

 

Pharmaceutical

 

$

318,073

 

 

$

320,847

 

Diagnostics

 

 

163,442

 

 

 

163,442

 

 

$

481,515

 

 

$

484,289

 

 

No customer represented more than 10% of our total consolidated revenue for the six months ended June 30, 2026 and 2025. As of June 30, 2026 and December 31, 2025, no customer represented more than 10% of our accounts receivable balance.